Renal function and continence of urine are critically dependent on the proper function of the urinary bladder, which stores urine at low pressure and expels it with a precisely orchestrated contraction. A number of congenital and acquired urological anomalies including posterior urethral valves, benign prostatic hyperplasia, and neurogenic bladder secondary to spina bifida/spinal cord injury can result in pathologic tissue remodeling leading to impaired compliance and reduced capacity 1 . Functional or anatomical obstruction of the urinary tract is frequently associated with these conditions, and can lead to urinary incontinence and kidney damage from increased storage and voiding pressures 2 . Surgical implantation of gastrointestinal segments to expand organ capacity and reduce intravesical pressures represents the primary surgical treatment option for these disorders when medical management fails 3 . However, this approach is hampered by the limitation of available donor tissue, and is associated with significant complications including chronic urinary tract infection, metabolic perturbation, urinary stone formation, and secondary malignancy 4, 5 . Current research in bladder tissue engineering is heavily focused on identifying biomaterial configurations which can support regeneration of tissues at defect sites. Conventional 3-D scaffolds derived from natural and synthetic polymers such as small intestinal submucosa and polyglycolic acid have shown some short-term success in supporting urothelial and smooth muscle regeneration as well as facilitating increased organ storage capacity in both animal models and in the clinic 6, 7 . However, deficiencies in scaffold mechanical integrity and biocompatibility often result in deleterious fibrosis 8 , graft contracture 9 , and calcification 10 , thus increasing the risk of implant failure and need for secondary surgical procedures. In addition, restoration of normal voiding characteristics utilizing standard biomaterial constructs for augmentation cystoplasty has yet to be achieved, and therefore research and development of novel matrices which can fulfill this role is needed.
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Current research in bladder tissue engineering is heavily focused on identifying biomaterial configurations which can support regeneration of tissues at defect sites. Conventional 3-D scaffolds derived from natural and synthetic polymers such as small intestinal submucosa and polyglycolic acid have shown some short-term success in supporting urothelial and smooth muscle regeneration as well as facilitating increased organ storage capacity in both animal models and in the clinic 6, 7 . However, deficiencies in scaffold mechanical integrity and biocompatibility often result in deleterious fibrosis 8 , graft contracture 9 , and calcification 10 , thus increasing the risk of implant failure and need for secondary surgical procedures. In addition, restoration of normal voiding characteristics utilizing standard biomaterial constructs for augmentation cystoplasty has yet to be achieved, and therefore research and development of novel matrices which can fulfill this role is needed.
In order to successfully develop and evaluate optimal biomaterials for clinical bladder augmentation, efficacy research must first be performed in standardized animal models using detailed surgical methods and functional outcome assessments. We have previously reported the use of a bladder augmentation model in mice to determine the potential of silk fibroin-based scaffolds to mediate tissue regeneration and functional voiding characteristics. 11, 12 Cystometric analyses of this model have shown that variations in structural and mechanical implant properties can influence the resulting urodynamic features of the tissue engineered bladders 11, 12 . Positive correlations between the degree of matrixmediated tissue regeneration determined histologically and functional compliance and capacity evaluated by cystometry were demonstrated in this model 11, 12 . These results therefore suggest that functional evaluations of biomaterial configurations in rodent bladder augmentation systems may be a useful format for assessing scaffold properties and establishing in vivo feasibility prior to large animal studies and clinical deployment. In the current study, we will present various surgical stages of bladder augmentation in both mice and rats using silk scaffolds and demonstrate techniques for awake and anesthetized cystometry.
Placing the Cystostomy Tube
1. Deliver the bladder through the incision. From this point on, the bladder should be handled with fine forceps to prevent trauma to the bladder that could cause damage or inflammation that can skew your cystometric results or result in additional discomfort for the animal postoperatively. 2. Make note of the proposed site for the cystostomy tube. It should be placed at the dome of the bladder (superior to the augment segment).
This will prevent kinking or occlusion of the tube. 3. Using the 6-0 polypropylene suture, place a pursestring stitch at the dome of the bladder in the following manner: place the first throw through the wall of the bladder longitudinally, lateral to the proposed site for the cystostomy tube. Leave a small clamp on the loose end so that the suture is not inadvertently pulled all the way through. Place the next throw in a transverse direction, starting first going into the bladder wall slightly lateral to the exit of your first throw. 4. Do not pull the suture taut. Place your next suture parallel to your first (longitudinally) going into the bladder just cephalad to the exit site of your last, transverse suture. The fourth throw will start lateral to the exit of the last stitch and end next to the entrance for your very first throw. Done correctly, this forms a circumferential square around the proposed catheter site (Figure 7) . 5. Using an 18G needle, pierce the bladder wall in the center of the pursestring suture. Be careful not to pierce too deeply (just enough to be intraluminal). Place the tips of your fine forceps in the opening and gently spread to widen the hole. 6. Insert the bulbed end of the catheter into the defect in the bladder until it is intraluminal. Pull the pursestring suture tight around the catheter and tie it down. This should cinch the bladder wall around the catheter keeping it in place (Figure 8 ). 7. Take one end of the suture and wrap it around the catheter once and tie this down to further secure the catheter.
Testing the Catheter and Closing the Abdominal Incision
1. With a 1 mL syringe and 25G needle, insert the needle into the tubing and slowly inject saline to distend the bladder. Observe for leaking around the catheter. Once you see leaking from the urethra, aspirate the saline to decompress the bladder again. 2. Close the abdominal incision as above in steps 4.1-4.4.
Closing the Dorsal Incision and Securing the Catheter (For rats)
1. Reposition the animal prone. 2. Cut the catheter tubing at the level of the skin with the scissors. Insert a 22G blunt tip needle into the tubing. 3. Close the skin over the tubing with 4-0 polyglactin in a running fashion. Leave the needle hub extruding from the skin. 4. Place an intravenous line cap on the blunt needle. Using 3-0 silk suture, secure the catheter tip to the skin (Figure 9 ). 5. Clean the incision. Transfer the rat into a warm, clean cage for awakening from the anesthesia.
8.* Closing the Dorsal Incision and Securing the Catheter (For mice or rats)
1. *Occlude the distal end of the catheter by kinking it or using a flame to melt the end. 2. *Coil the end of the tubing and leave it in the subcutaneous pouch on the dorsum of the animal (do NOT cut tubing to shorten it) (Figure 10 ). 3. *Close the skin over the tubing with 4-0 polyglactin in a running fashion (Figure 11 ). 4. *On the day of cystometry, prepare the dorsal incision with betadine and 70% ethanol. Open the dorsal incision under anesthesia and remove the coiled tubing from the subcutaneous pouch. Close the incision. Awaken the animal from anesthesia and perform cystometry when it is fully awake.
Representative Results -Surgical Methods
The reconstructed bladder should be as water-tight as possible to avoid complications related to a significant urinary leak (Figure 3) . Pain or discomfort usually manifest as shivering or scratching and gnawing at the abdominal incision. This can be managed with daily subcutaneous injections of a non-steroidal anti-inflammatory such as meloxicam (0.5-1.0 mg/kg subcutaneous). Typically, the animals only require the injections for the first 3 days post-operatively. This can be supplemented with an opioid, such as buprenorphine (0.05-0.1 mg/kg subcutaneous every 8-12 hr) as needed. The animals should be monitored 3 times daily for the first 3 post-operatively days, twice daily for post-operative days 3-5 and then daily thereafter to evaluate for pain, signs of infection, adequate wound healing, activity, grooming, and skin turgor. Antibiotics (Baytril, 5mg/ kg subcutaneous every 24 hr in a volume not exceeding 0.1 mL) are given for the first 72 hr following surgery, as surgical prophylaxis against infection. Signs of normal recovery are normal ambulation and activity levels, appropriate feeding and drinking, absence of pain or distress (no vocalization) and normal socialization with cagemates. A recovery time of at least 5-7 days should be given before cystometric analysis, to allow for bladder healing and decreased inflammation which could potentially affect the results.
Cystometric Analyses
10. Awake Cystometric Analysis . Connect the data capture system to a computer and observe for data tracings. Adjust the scale accordingly. Bladder pressure and urine volume will be continuously recorded. 6. Access the suprapubic catheters with a 27G needle connected via a T-tube to the pressure transducer and the infusion pump. Begin the infusion of physiologic saline at 12.5 μL/min for the mouse and 100 μL/min for the rat. 7. Allow the voiding pattern tracing to stabilize (bladder pressure rise, followed by a void). This usually takes approximately 10-20 minutes.
Record the micturition cycles for 45-120 minutes or at least 3-4 voiding cycles. 8. Observe entire procedure in real-time to troubleshoot for complications that will lead to artifact (i.e. catheter kinking, obstruction, etc; see below discussion). 9. Stop the infusion, disconnect the catheter from the system, and return the animal to its cage.
Unconscious Cystometric Analysis (No suprapubic catheter)
1. Anesthetize the animal with urethane (1-2 g/kg) intraperitoneal injection (IP). 2. Expose the bladder as above in steps 1.3-2.4. 3. Calibrate the system as in step 9.2. Prepare the system as in step 9.4-9.5. 4. Insert a 27G needle connected via a T-tube to the pressure transducer and infusion pump into the lateral aspect of the bladder. 5. Record the micturition cycles for 45-90 minutes. 6. Stop the infusion, remove the needle from the bladder and euthanize the animal.
Representative Results -Cystometric Analyses
Urodynamic tracings can then be analyzed to derive parameters such as voided volumes, compliance, peak voiding pressures, inter contraction interval, micturition cycle time and post void residual volumes.
Cystometrogram can be divided into a filling and a voiding phase. A normal filling phase is the portion of the micturition cycle in which bladder fills with very little change in intravesical pressure. A normal voiding phase of the tracing consists of a steady rise in the intravesical pressure corresponding to the detrusor contraction. The highest pressure reached during the voiding phase of the tracing is termed the peak voiding pressure. A high peak voiding pressure could suggest an obstructive voiding pattern, a hypercontractile bladder or a kink in the SP catheter. Compliance can be calculated by acquiring the ratio of the volume instilled during the filling phase and the change in pressure (compliance = ΔV/ ΔP). A hypocompliant bladder is one that is unable to accommodate adequate urinary volumes at low pressures. The intercontraction interval can be calculated by analyzing the time between two contractions as seen on the cystometrogram. A short intercontraction interval is suggestive of an irritable bladder. The micturition cycle time refers to the time it takes for an entire filling and voiding phase to complete and can be easily ascertained by analyzing the tracing. At the conclusion of the cystometry, post-void residual (PVR) can be obtained. This is done by aspirating the suprapubic catheter upon the completion of a detrusor contraction. These parameters help the investigator objectively study the bladder dynamics as the bladder fills and empties. 
Discussion
Cystometric evaluations of biomaterial configurations following implantation and bladder augmentation in small animal models represents an important validation step in identifying optimal structural and mechanical characteristics of matrix designs for use in clinical situations. In this study, we describe surgical methods for performing bladder augmentation in mice and rats as well as cystometric techniques to determine urodynamic properties of engineered organs for functional assessments. We have utilized these techniques in multiple experiments involving both mice and rats, with each experiment consisting of 30+ rodents without significant issues. Our research laboratory is a diverse conglomerate of basic scientists and physician surgeons, and surgeons with at least 5-6 years of post-graduate surgical training performed the procedural aspects of these experiments.
Regardless of the type of biomaterial used, the major difference between augmenting the bladder in rats versus mice is the size of the bladder. Due to smaller bladder size, dissection and incorporation of the biomaterial is more technically difficult in the mouse. To aid in visualization, a surgical microscope can be used. Since the size of the bladder in rats is larger, it is more amenable to situations where more than one procedure has to be performed on the bladder (e.g. augmentation and placement of cystostomy catheter). Additionally, the protocol above describes use of PE-50 tubing for the rat 13 , however, even larger size catheters, up to PE-100 have been used, especially for long-term studies 14 . In mice, a smaller caliber such as PE-10 tubing can be utilized 15, 16 , but it should be kept in mind that smaller, more pliable tubes may not transmit pressure changes to the transducer accurately. Also, the alternative method of securing the catheter on the dorsum (step 8* above) is done in mice due to their smaller body size and the blunt tip needle and IV cap are too cumbersome. The disadvantage of this is the need for anesthesia to extract the end of the catheter in the subcutaneous pouch prior to cystometry.
Studies have shown that in the initial first days (0-4 days) after placement of the catheters, cystometry revealed high bladder pressures and overactivity with low voiding volumes. These findings appeared to stabilize around the sixth to seventh day 14, 17 and therefore, is probably the ideal timing for cystometric evaluation. However, most reports in the literature perform cystometry within the first 3 days of catheterization 18 , and this accounts for the wide variation in the above parameters relative to time. Leaving the suprapubic catheter for a duration longer than 3 days carries with it morbidities such as risk of stones, dislodgement, infection, hematuria and occlusion of catheter with debris.
Different infusion rates during cystometry have been described from 1-3mL/hr for mice 15, 16 and 10-11mL/hr for rats 13, 19, 20 . Supraphysiologic infusion rates can cause falsely elevated pressures 14 . We use an infusion rate of 12.5 μL/min (0.75 mL/hr) for mice and 100 μL/min (6 mL/ hr) for rats in our setup, but lower rates can also be utilized. The temperature of the physiologic saline should be at least room temperature, although warm (37°) saline is more optimal in order to avoid bladder overactivity provoked with instilling cold solution. In awake cystometry, it is crucial to allow for stabilization of the voiding pattern as the animal becomes adjusted to the cage, which in our experience requires a period of ~10-20 minutes. Following this, regular micturition cycles can be recorded for 45-120 minutes or at minimum 3-4 voiding cycles. The animal should be observed in real-time since the animal is freely moving and complications such as twisting or kinking of the catheter can alter cystometric analysis. Limiting environmental noise during cystometry is desired to decrease animal movement and subsequent artifacts. Unconscious cystometry does not have the attendant problems as awake cystometry, but multiple anesthetics have been shown to inhibit spontaneous bladder contractions. This inhibition corresponds directly to the expected duration of action of the anesthetic drugs, i.e. when the anesthetic effect subsides, spontaneous contractions resume 14 . Moreover, pressures measured when the bladder overflowed, were statistically greater in anesthetized rats, both alive and post-mortem, indicating an effect on the passive compliance properties of the bladder wall. This effect is seen with pentobarbital 21 , ketamine, and chloralose IM/IP, in addition to inhaled halothane and intrathecal nesacaine 14 . A more extensive study of various anesthetics confirm this finding with suppression of the micturition reflex for both inhalational (isoflurane and methoxyflurane) and barbiturate (pentobarbital and thiobutabarbital) anesthetics under moderate anesthesia levels 17 . This effect was observed with even light or sedative levels of anesthesia with medications such as fentanyl-droperidol and ketamine-diazepam, and as in the previous study, as the anesthesia effect subsided, so did the inhibition 17 . For this procedure, urethane intraperitoneal injections can be used since it has been demonstrated that reflex micturition is preserved while also allowing for adequate anesthesia 17, 22 . Moreover, no effect is observed with respect to micturition pressures 23 . Suprapubic catheter placement for cystometry is described here, since intraurethral catheterization has been shown to have higher bladder pressure curves and lower flow rates consistent with relative bladder outlet obstruction 24 . Moreover, intraurethral catheterization is only feasible in anesthetized animals, and even then, catheterization can be difficult, especially in male rodents and mice.
In conclusion, the choice of which model to use for bladder augmentation and/or cystometric analysis is dependent on the goals of the specific study. From a technical standpoint the rat model clearly holds the advantage for the reasons discussed above. However, the mouse model
